• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

    9/16/24 6:50:00 AM ET
    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALIM alert in real time by email

    PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM).

    The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions.

    About ANI Pharmaceuticals, Inc.

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. ANI is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, visit our website www.anipharmaceuticals.com.

    Forward-Looking Statements

    This communication, and the documents to which it refers you, contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the parties' expectations or beliefs concerning future events, including the timing of the transaction and other information relating to the transaction. Forward-looking statements include information concerning the expected completion and timing of the transaction and other information relating to the transaction. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "forecasts," "should," "estimates," "contemplate," "future," "goal," "potential," "predict," "project," "projection," "may," "will," "could," "should," "would," "assuming" and similar expressions are intended to identify forward-looking statements. You should read statements that contain these words carefully. They discuss ANI's and/or Alimera's future expectations or state other forward-looking information and may involve known and unknown risks over which the parties have no control. Forward-looking statements speak only as of the date of this communication or the date of any document incorporated by reference in this document. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are described in the parties' respective SEC reports. Except as required by applicable law or regulation, neither party undertakes to update these forward-looking statements to reflect future events or circumstances.

    Investor and/or Media Contacts:

    Lisa M. Wilson, In-Site Communications, Inc.

    212-452-2793

    [email protected]



    Primary Logo

    Get the next $ALIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALIM
    $ANIP

    CompanyDatePrice TargetRatingAnalyst
    ANI Pharmaceuticals Inc.
    $ANIP
    3/14/2025$80.00Buy
    Jefferies
    ANI Pharmaceuticals Inc.
    $ANIP
    3/12/2025$85.00Overweight
    Analyst
    ANI Pharmaceuticals Inc.
    $ANIP
    12/11/2024$80.00Outperform
    Leerink Partners
    ANI Pharmaceuticals Inc.
    $ANIP
    10/11/2024$68.00Overweight
    Piper Sandler
    Alimera Sciences Inc.
    $ALIM
    6/25/2024Buy → Neutral
    H.C. Wainwright
    Alimera Sciences Inc.
    $ALIM
    3/25/2024$10.00Buy
    Maxim Group
    ANI Pharmaceuticals Inc.
    $ANIP
    3/15/2024$80.00Overweight
    CapitalOne
    Alimera Sciences Inc.
    $ALIM
    10/30/2023$8.00Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $ALIM
    $ANIP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

      PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date:Tuesday, May 20, 2025  Time:1:30pm ET  Webcast:Click Here   To schedule a 1x1 meeting with management, please contact [email protected]. The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About

      5/12/25 6:30:00 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

      Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. "In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "The results further support our understandin

      5/5/25 7:00:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    Financials

    Live finance-specific insights

    See more
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section           A re

      4/9/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0 million, which includes: Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 million, an increase of 42.3% year-over-year, andILUVIEN® and YUTIQ® net revenues of $27.6 million in the first full quarter of ownership following the acquisition of Alimera Sciences Delivered record quarterly adjusted non-GAAP EBITDA of $50.0 million, an increase of 65.7% year-over-yearDiluted GAAP loss per share of $(0.55) and adjusted non-GAAP diluted earnings per share of $1.63Increased 2025 guidance with expected net revenu

      2/28/25 6:50:16 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

      Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

      3/8/21 5:11:24 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXYCODONE AND ASPIRIN

      Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

      3/8/21 5:11:06 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for EZETIMIBE AND SIMVASTATIN

      Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

      2/25/21 5:09:42 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ANI Pharma with a new price target

      Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00

      3/14/25 7:26:09 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on ANI Pharma with a new price target

      Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00

      3/12/25 7:20:36 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on ANI Pharma with a new price target

      Leerink Partners initiated coverage of ANI Pharma with a rating of Outperform and set a new price target of $80.00

      12/11/24 7:21:57 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    Leadership Updates

    Live Leadership Updates

    See more
    • Alcami Announces CEO Transition

      Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

      1/13/25 11:12:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.  "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

      12/12/23 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Appoints Maggie A. Pax to Its Board of Directors

      ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

      11/8/23 4:30:00 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

      SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      11/13/24 4:30:24 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      9/18/24 4:30:11 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      9/16/24 5:10:24 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $24,880 worth of shares (400 units at $62.20), decreasing direct ownership by 0.50% to 79,745 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      5/13/25 4:29:47 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HEAD OF R&D, COO-NOVITIUM OPS Shanmugam Muthusamy sold $53,781 worth of shares (700 units at $76.83) (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      5/13/25 4:21:52 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $27,584 worth of shares (400 units at $68.96), decreasing direct ownership by 0.50% to 80,145 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      4/14/25 4:17:11 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    $ANIP
    SEC Filings

    See more
    • SEC Form 10-Q filed by ANI Pharmaceuticals Inc.

      10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/9/25 6:57:59 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/9/25 6:55:20 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ANI Pharmaceuticals Inc.

      DEFA14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/8/25 9:15:39 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care